LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・MacroGenics Inc

MacroGenics Inc

Suletud

Sektor Tervishoid

3.26 -2.98

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.23

Max

3.27

Põhinäitajad
By Trading Economics
Sissetulek	-52M
Müük	-1.6M 9.1M
Aktsiakasum	-0.84
Kasumimarginaal	-573.264
Töötajad	339
EBITDA	-49M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+114.5 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. nov 2024

Turustatistika
By TradingEconomics
Turukapital	-6.6M 219M
Eelmine avamishind	6.24
Eelmine sulgemishind	3.26

Uudiste sentiment

By Acuity

86%

14%

327 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

3.24 / 3.38 Toetus ja vastupanu

MacroGenics Inc Graafik

Seotud uudised

7. sept 2024, 09:30 UTC

Peamised uudised

Jobs Slowdown Frustrates Investors Who Wanted Certainty on the Fed -- WSJ

7. sept 2024, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

6. sept 2024, 22:41 UTC

Market Talk

KinderCare and StandardAero File for IPOs -- Market Talk

6. sept 2024, 21:18 UTC

Peamised uudised

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6. sept 2024, 21:05 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6. sept 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. sept 2024, 20:39 UTC

Tulu

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6. sept 2024, 20:35 UTC

Peamised uudised

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6. sept 2024, 20:34 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6. sept 2024, 20:11 UTC

Peamised uudised

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6. sept 2024, 19:51 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6. sept 2024, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Hold Gains -- Market Talk

6. sept 2024, 19:14 UTC

Market Talk

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6. sept 2024, 19:01 UTC

Market Talk

Gold Slips on Prevailing Uncertainty -- Market Talk

6. sept 2024, 18:27 UTC

Peamised uudised

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6. sept 2024, 18:25 UTC

Market Talk

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6. sept 2024, 18:15 UTC

Peamised uudised

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6. sept 2024, 18:12 UTC

Peamised uudised

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6. sept 2024, 17:44 UTC

Market Talk

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6. sept 2024, 17:30 UTC

Market Talk

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6. sept 2024, 17:30 UTC

Peamised uudised

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6. sept 2024, 17:27 UTC

Peamised uudised

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6. sept 2024, 17:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. sept 2024, 17:00 UTC

Market Talk

Mexican Inflation Seen Easing in August -- Market Talk

6. sept 2024, 16:36 UTC

Market Talk

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6. sept 2024, 16:35 UTC

Tulu

Kuumad aktsiad

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6. sept 2024, 16:33 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6. sept 2024, 16:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

6. sept 2024, 16:20 UTC

Tulu

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6. sept 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

114.5% tõus

12 kuu keskmine prognoos

Keskmine 7.25 USD 114.5%

Kõrge 14 USD

Madal 4 USD

Põhineb 12 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi MacroGenics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.24 / 3.38Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

327 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest MacroGenics Inc

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.